StreetInsider.com News Articles

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical development program within The Bahamas' growing longevity and regenerative-medicine sector.

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Wed, 07 Oct 2026 14:37:00 -0400

Further to its September 23, 2026 announcement, Hemostemix has submitted a Form 4B to the TSX Venture Exchange seeking price protection

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it is presenting at the Centurion One Capital 4th Annual Bahamas Summit at Rosewood Baha Mar in Nassau, The Bahamas, October 19 to October 21, 2026.

The invitation-only summit brings together company executives, institutional investors and family offices for company presentations, panel discussions and one-on-one meetings. Hemostemix intends to discuss VesCell™ commercialization in The Bahamas on the foundation of VesCell's clinical evidence - 498 treatments, seven clinical studies and 11 peer reviewed publications.

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit

Mon, 28 Sep 2026 14:45:00 -0400

The Bahamas clinical program

Hemostemix

Hemostemix files Form 4B for third tranche of private placement

Wed, 23 Sep 2026 16:11:13 -0400

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) is filing a Form 4B to obtain price protection for the closing of the third tranche of a non-brokered private placement, according to a company statement. The offering, first announced June 17, 2026, aims to raise $1,000,000.

Each unit in the offering consists of one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at CDN$0.12 per share for 24 months from the closing date of the third tranche. If the volume-weighted average trading price of common shares on the TSX Venture

Hemostemix files Form 4B for third tranche of private placement

Wed, 23 Sep 2026 16:11:13 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to acquire one additional

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Hemostemix Non Brokered Private Placement

Wed, 23 Sep 2026 16:10:00 -0400

Form F-6EF Hemnet Group AB/ADR Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary

Tue, 20 Jan 2026 15:50:00 -0400

si-local-file:///var/storage/secattach/20260120/25867966.html

Form F-6EF Hemnet Group AB/ADR Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary

Tue, 20 Jan 2026 15:50:00 -0400

si-local-file:///var/storage/secattach/20260120/25867966.html

Form F-6EF Hemnet Group AB/ADR Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary

Tue, 20 Jan 2026 15:50:00 -0400

si-local-file:///var/storage/secattach/20260120/25867966.html

Life Science Virtual Investor Forum Agenda Announced for September 18th